

## Stakeholder Opinions: Gene Therapy - Gene therapy to deliver after 20 years of clinical development

---

Published: 2009-DEC-10

Pages: 90

Format: PDF & SlidePack

Price: 3800 USD (Single User License)

### Description

#### Introduction

Gene therapy looks to be coming of age, with seven projects in Phase III clinical development and one project currently under regulatory review. A shift in development from pure gene replacement to using gene therapy as a therapeutic delivery tool has enhanced the technology's commercial potential over the last 10 years.

#### Scope

\*In-depth analysis of the current gene therapy clinical pipeline.

\*Analysis of key target indications for gene therapies and key companies active in the field.

\*Key opinion leader review of technologies driving clinical gene therapy.

\*Identification of drivers and inhibitors to the commercial success of gene therapy.

#### Highlights

Most of the indications being targeted in the current gene therapy pipeline are multifactorial rather than monogenic in etiology. Reflecting this trend, cancer has become the leading therapy area for gene therapy development, constituting nearly half of the clinical projects under development.

The development of highly engineered recombinant viruses has increased the safety of gene therapy. As clinical evidence for the enhanced safety of these vectors gathers over the next few years, the perceived risk/reward profile for gene therapy will change in some disease areas.

With endless lucrative targets for companies developing safe and efficient delivery of genes, the commercial potential of gene therapy remains high.

#### Reasons to Purchase

\*Quantify the gene therapy pipeline.

\*Assess the changing vectors and target indications for gene therapy.

\*Identify the leading companies involved in gene therapy development.

### Table of Contents

Overview 1

Catalyst 1

Summary 1

About Datamonitor healthcare 2

About the healthcare research & analysis team 2

Executive Summary 3

Scope of the analysis 3

Datamonitor insight into the gene therapy market 3

# BioMarket Group - A Global Online Aggregator of Life Science Market Research

Related reports	4
Upcoming reports	4
Table of Contents	5
1. Market Overview	6
Key findings	6
Market definition for this report	7
Clinical trial trends 1989-2009	7
A timeline of clinical gene therapy	7
Geographic distribution of gene therapy clinical trials, 1989-2009	11
Current market	12
Gendicine (SiBiono, a subsidiary of Benda Pharmaceuticals, China)	12
Factors leading Gendicine to become the first commercially available gene therapy	13
Commercial success of Gendicine	13
Clinical efficacy	14
Safety of Gendicine	15
Lessons from Gendicine	16
Rexin-G (Epeius Biotechnologies, Philippines)	16
Current pipeline	16
Phase III and pre-approval projects	17
Collategene (AnGes and Daiichi Sankyo)	18
Glybera (Amsterdam Molecular Therapeutics)	18
Cerepro (Ark Therapeutics)	19
Genex (Cardium Therapeutics)	19
TNFERade (GenVec)	20
TK007 (MolMed)	20
XRP0038 (Sanofi-Aventis)	20
Allovectin-7 (Vical)	21
Broad applicability across disease types	22
Key therapy areas	23
Most frequently targeted indications	25
Cancer	26
Cancer types targeted by gene therapy	27
Pancreatic cancer	29
Head and neck cancer	30
Breast cancer	31
Prostate cancer	32
Central nervous system	32
Parkinson's disease	33
Leber congenital amaurosis (retinal disorder)	35
Multi-indication potential of nerve growth factor	35
Cardiovascular and circulatory system	36
Peripheral arterial disease	37
Key companies	39
2. Technology Review	41
Key findings	41
Gene therapy methods	42
Ex vivo gene therapy	42
In vivo gene therapy	43
Delivery of genes	43
Different delivery mechanisms for different situations	45
Viral vectors	46
Movement towards adeno-associated viruses vectors	47
Adenovirus	49
Retrovirus	50
Adeno-associated viruses	53
Mechanical delivery	56
Gene regulation	58
Regulatable vectors	58
3. Commercial Considerations	60
Key findings	60
Key drivers to commercial success	61
Endless lucrative targets for companies mastering delivery	61
Access to previously untapped markets	61
Key inhibitors to commercial success	62
Safety	62
Immune response	63
Mutagenesis	64
Germline transmission	64
Funding and Big Pharma involvement	64
Academic funding	64
Big Pharma involvement	65
Reliable delivery and regulatable expression	67
Challenging to treat multifactorial diseases	68
Access to vectors	68
Stigma associated with gene therapy	69
Market entry strategies	69

# BioMarket Group - A Global Online Aggregator of Life Science Market Research

Pricing	71
Regulation	72
US	72
FDA - Center for Biologics Evaluation and Research (CBER)	72
NIH - Recombinant DNA Advisory Committee (RAC)	73
Europe	73
European Medicines Agency (EMA)	73
Germany	74
UK	74
France	74
Bibliography	76
Journals	76
Websites	78
Datamonitor reports	80
Appendix A	82
Raw data	82
Appendix B	86
Contributing experts	86
Report methodology	86
About Datamonitor	87
About Datamonitor Healthcare	87
About the healthcare research & analysis team	88
Disclaimer	90
List of Tables	
Table 1: Gendicine efficacy in head and neck squamous cell carcinoma	15
Table 2: Gendicine follow-up survival data in head and neck squamous cell carcinoma	15
Table 3: Phase III and pre-approval gene therapy projects, 2009	18
Table 4: Gene therapy methods for the treatment of cancer	27
Table 5: Gene therapies in development for pancreatic cancer, 2009	29
Table 6: Gene therapies in development for head and neck cancer, 2009	30
Table 7: Gene therapies in development for breast cancer, 2009	31
Table 8: Gene therapies in development for prostate cancer, 2009	32
Table 9: Gene therapies in development for Parkinson's disease, 2009	34
Table 10: Gene therapies in development for Leber congenital amaurosis (retinal disorder), 2009	35
Table 11: Gene therapies in development for peripheral arterial disease, 2009	38
Table 12: Vector system properties	46
Table 13: Advantages and disadvantages of the adenoviral vector in gene therapy	49
Table 14: Advantages and disadvantages of the lentiviral vector in gene therapy	51
Table 15: Advantages and disadvantages of the adeno-associated viral (AAV) vector in gene therapy	53
Table 16: Clinical programs in development using gene therapy, 2009	83
List of Figures	
Figure 1: Timeline of gene therapy clinical development	10
Figure 2: Number of gene therapy clinical trials approved worldwide, 1989-2008	11
Figure 3: Geographic distribution of gene therapy clinical trials, 1989-March 2009	12
Figure 4: Number of clinical trials for gene therapy at each stage of development, 2009	17
Figure 5: Phase II results investigating high-dose Allovectin-7 in recurrent or unresponsive Stage III/IV melanoma	21
Figure 6: Number of gene therapy clinical projects underway for each therapy area, 2009	23
Figure 7: Number of genes in clinical trials for each therapy area, 2009	24
Figure 8: Number of gene therapy clinical projects underway by stage for key therapy areas, 2009	25
Figure 9: Indications with three or more clinical projects in development, 2009	26
Figure 10: Number and stage of development for cancer gene therapy programs, 2009	28
Figure 11: Number and stage of development for CNS gene therapy programs, 2009	33
Figure 12: Number and stage of development for cardiovascular and circulatory system gene therapy projects, 2009	37
Figure 13: Key companies with gene products in clinical development, 2009	40
Figure 14: In vivo versus ex vivo gene therapy	42
Figure 15: Vectors used in gene therapy clinical trials, 1989-March 2009	44
Figure 16: Vectors used in gene therapy clinical trials, 2009	45
Figure 17: A typical virus replication cycle	47
Figure 18: Virus types used as gene therapy vectors in clinical trials, 1989-March 2009	48
Figure 19: Virus types used as gene therapy vectors in clinical trials, 2009	49

## Ordering

Order Online - <http://www.biomarketgroup.com/market-research-report/stakeholder-opinions-gene-therapy-gene-therapy-to-deliver-after-20-years-of-clinical-development.html>

Order by Fax - using the form below

Order by Post - print the order form below and send to:

BioMarket Group  
Björnåsvägen 21

**BioMarket Group - A Global Online Aggregator of Life Science Market Research**

11419 STOCKHOLM  
SWEDEN

## Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to +46-8-56849191. If you have any questions please visit <http://www.biomarketgroup.com/market-research-report/contacts/>

### Order Information

Please verify that the product information is correct:

Product Name: **Stakeholder Opinions: Gene Therapy - Gene therapy to deliver after 20 years of clinical development**

Web Address: <http://www.biomarketgroup.com/market-research-report/stakeholder-opinions-gene-therapy-gene-therapy-to-deliver-after-20-years-of-clinical-development.html>

Format: PDF & SlidePack

Price: 3800 USD (Single User License)

Delivery of hard copy or CD-ROM is subject to a Courier charge of 50 USD.

### Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: \_\_\_\_\_

Name: \_\_\_\_\_

Email Address:\* \_\_\_\_\_

Job Title: \_\_\_\_\_

Organization: \_\_\_\_\_

EU companies must supply: VAT / BTW / MOMS

MWST / IVA / FPA number: \_\_\_\_\_

Address: \_\_\_\_\_

Zip Code: \_\_\_\_\_

City: \_\_\_\_\_

State: \_\_\_\_\_

Country: \_\_\_\_\_

Phone Number: \_\_\_\_\_

Fax Number: \_\_\_\_\_

### Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:**
- American Express
  - Master Card
  - Visa

Cardholder Name: \_\_\_\_\_

Expiry Date (MM/YY): \_\_\_\_\_

Card Number: \_\_\_\_\_

CVV Number: \_\_\_\_\_

- Pay by check:**

Please post the check, accompanied by this form, to:  
BioMarket Group  
Björnnäsvägen 21  
11419 STOCKHOLM  
SWEDEN

- Pay by wire transfer:** Please transfer funds to:

Account number: 43521169

Swift code: HANDSESS

IBAN number: SE74 6000 0000 0000 4352 1169

Bank Address: Handelsbanken, Stockholm, Sweden

If you have a Marketing Code please enter it below:

Marketing Code: \_\_\_\_\_

Please supply purchase order number if needed: \_\_\_\_\_

\* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, Gmail)

Please note that by ordering from BioMarket Group you are agreeing to our Terms and Conditions at

<http://www.biomarketgroup.com/market-research-report/biomarket-group-full-terms-and-conditions/>

**Please fax this form to: +46-8-56849191**